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Introduction
Regulation of muscle contraction is an intricate interplay 
between the actin-based thin filament and the myosin-based 
thick filament, both key components of the sarcomere, the 
smallest contractile unit in muscle (Figure 1A). During muscle 
activation, the number of force-generating myosin molecules 
(i.e., cross bridges) rapidly builds and high forces are generated; 
during relaxation, this number rapidly falls to bring force down 
and allow lengthening of passive muscle to occur. The kinetics 
of muscle activation have been widely studied, but relaxation 
is much less well understood, despite its crucial importance for 
muscle contractility and disease (1–3). A prime example of the 
impact of impaired relaxation kinetics on muscle contractility is 
nemaline myopathy (NEM), caused by mutations in KBTBD13 
(NEM6). In addition to weakness, NEM6 patients have slow 
muscle relaxation (4–6), which impairs their ability to perform 
fast movements, e.g., running or climbing the stairs (see Supple-
The mechanisms that modulate the kinetics of muscle relaxation are critically important for muscle function. A prime 
example of the impact of impaired relaxation kinetics is nemaline myopathy caused by mutations in KBTBD13 (NEM6). In 
addition to weakness, NEM6 patients have slow muscle relaxation, compromising contractility and daily life activities. The 
role of KBTBD13 in muscle is unknown, and the pathomechanism underlying NEM6 is undetermined. A combination of 
transcranial magnetic stimulation–induced muscle relaxation, muscle fiber– and sarcomere-contractility assays, low-angle 
x-ray diffraction, and superresolution microscopy revealed that the impaired muscle-relaxation kinetics in NEM6 patients are 
caused by structural changes in the thin filament, a sarcomeric microstructure. Using homology modeling and binding and 
contractility assays with recombinant KBTBD13, Kbtbd13-knockout and Kbtbd13R408C-knockin mouse models, and a GFP-
labeled Kbtbd13-transgenic zebrafish model, we discovered that KBTBD13 binds to actin — a major constituent of the thin 
filament — and that mutations in KBTBD13 cause structural changes impairing muscle-relaxation kinetics. We propose that 
this actin-based impaired relaxation is central to NEM6 pathology.
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this pathomechanism. As the vast majority of genes implicated in 
NEM encode thin-filament–associated proteins, we hypothesized 
that the impaired muscle-relaxation kinetics in NEM6 patients are 
caused by changes in thin-filament structure and function.
To test this hypothesis, we applied techniques to study mus-
cle relaxation at various levels of organization, ranging from the 
patient in vivo to individual sarcomeres isolated from patient 
biopsies. A combination of transcranial magnetic stimulation–
induced (TMS-induced) in vivo muscle-relaxation studies, in vitro 
muscle fiber– and sarcomere-contractility assays, and low-an-
gle x-ray diffraction and superresolution microscopy revealed 
that the impaired muscle-relaxation kinetics in NEM6 patients 
is thin filament based. Using homology modeling, binding, and 
contractility assays with recombinant KBTBD13, Kbtbd13-KO 
and Kbtbd13R408C-knockin (Kbtbd13R408C-KI) mouse models, and 
a GFP-labeled Kbtbd13-transgenic zebrafish model, we discov-
ered that KBTBD13 is an actin-binding protein and that muta-
tions in KBTBD13 affect the kinetics of muscle relaxation through 
effects on thin-filament structure. Hence, this study identifies (a) 
KBTBD13 as a regulator of skeletal muscle relaxation and (b) the 
pathomechanism underlying muscle dysfunction in NEM6 myop-
athy as thin-filament–based impaired muscle-relaxation kinetics.
Results
Lower muscle force and slower relaxation kinetics in NEM6 patients in vivo
Patient characteristics are shown in Table 1. In vivo muscle force 
and relaxation kinetics of deep-finger flexors were determined 
using noninvasive TMS (25) (Figure 2A). Maximal force was low-
er in NEM6 patients than in control subjects, both in males and 
in females (Figure 2B). Because relaxation kinetics were similar 
between males and females, these data were pooled. Figure 2A 
shows a typical relaxation trace of a patient and control subject 
with marked slower muscle relaxation. The normalized peak 
relaxation rate was lower in NEM6 patients than in controls (Fig-
ure 2C), and accordingly, the 75% relaxation time (time for force 
to drop by 25%) was longer in NEM6 patients than in controls (Fig-
ure 2D). This demonstrates that the origin of slower muscle relax-
ation in NEM6 patients is myogenic.
Lower contractile force and slower relaxation kinetics in NEM6 
muscle fibers
First, we studied whether changes in Ca2+ handling proteins con-
tributed to impaired muscle relaxation in NEM6. The level of SER-
CA1, a key protein involved in sarcoplasmic reticulum Ca2+ han-
dling in fast-twitch fibers, was not significantly different between 
NEM6 and control muscle (Supplemental Figure 1, A and B). SER-
CA1 protein levels and SERCA activity strongly correlated with 
mental Videos 1–3; supplemental material available online with 
this article; https://doi.org/10.1172/JCI124000DS1), and to pre-
vent themselves from falling when tripping.
NEMs are among the most common nondystrophic congen-
ital myopathies (7). So far, 13 genes have been implicated: α-ac-
tin 1 (ACTA1) (8), α- and β-tropomyosin (TPM3 and TPM2) (9, 
10), nebulin (NEB) (11), leiomodin-3 (LMOD3) (12), troponin T 
(TNNT1) (13) and TNNT3 (14), cofilin 2 (CFL2) (15), unconven-
tional myosin 18B (MYO18B) (16), myopalladin (MYPN) (17), Kelch 
family members 40 (KLHL40) and -41 (KLHL41) (18, 19), and 
Kelch repeat and BTB (POZ) domain containing 13 (KBTBD13) 
(20). Eleven out of these thirteen genes encode proteins that are 
associated with the actin-based thin filament, and recent studies 
revealed that thin-filament dysfunction is a major contributor to 
muscle weakness in NEM (12, 21–23). Hence NEM is considered a 
disease of the thin filament.
Interestingly, KBTBD13 has no established association with 
the thin filament (Figure 1B). In fact, the localization and function 
of KBTBD13 are obscure (24), and therefore, the pathomechanism 
underlying weakness and impaired relaxation kinetics of muscle in 
NEM6 patients is unknown. The goal of this study was to discover 
Figure 1. Schematic of muscle from the macroscopic to the nanoscopic 
level. (A) Simplified schematic of a skeletal muscle fiber, myofibril, sar-
comere, and thick and thin filaments: key components of muscle activa-
tion and relaxation. (B) Simplified schematic of the skeletal muscle thin 
filament. The majority of genes implicated in NEM encode thin- filament 
(associated) proteins. For KBTBD13, the localization and function are 
unknown. Arrows indicate direct associations; dotted arrows indicate 
indirect associations.
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As phospholamban slows SERCA activity, this might contribute 
to slower muscle relaxation in NEM6. Electron microscopy (EM) 
analyses showed no aberrations in the structure of the triads in 
muscle fibers of NEM6 patients.
the area of fast-twitch fibers in muscle biopsies of NEM6 patients 
(Supplemental Figure 1, C–E). The ratio of phospholamban (active 
form) over phosphorylated phospholamban (inactive form) was 
increased in NEM6 muscle biopsies (Supplemental Figure 1F). 
Table 1. Clinical characteristics and genetic information of patients and controls
Study ID  
TMS
Study ID 
biopsy
Sex Onset Age at 
biopsy
Age at  
TMS
Muscle weaknessA  
at time of biopsy/ 
first consultation
Reported muscle  
slowness/stiffness
Result of biopsy KBTBD13 mutation
NEM6-T05 NEM6-F01 F Childhood 42 49 MildB Stiffness Cores and dystrophy c.1222C>T 
(p.(Arg408Cys))
NEM6-F02 F Adulthood 43 NA Mild Stiffness Cores and rods c.1222C>T 
(p.(Arg408Cys))
NEM6-T03 NEM6-F03 F Childhood 16 28 Mild Slowness Rods No genetic confirmation 
Mother with c.1222C>T 
(p.(Arg408Cys)) 
mutation
NEM6-F04 F Adolescence 45 NA Mild Stiffness and  
slowness
Cores and rods c.1222C>T 
(p.(Arg408Cys))
NEM6-F05 M Adulthood 62 NA Mild Stiffness Normal c.1222C>T 
(p.(Arg408Cys))
NEM6-F06 F Adolescence 34 NA ModerateC None Rods c.1222C>T 
(p.(Arg408Cys))
NEM6-F07 F Childhood 28 NA No muscle  
weakness
Stiffness Normal c.247G>C 
(p.(Glu83Gln))
NEM6-F08 M Childhood 68 NA Moderate Slowness Rods c.1222C>T 
(p.(Arg408Cys))
NEM6-F09 F Unknown 45 NA Unknown Unknown Cores and rods c.1222C>T 
(p.(Arg408Cys))
NEM6-F10 F Childhood 56 NA Mild Slowness Rods c.1222C>T 
(p.(Arg408Cys))
NEM6-T07 NEM6-F11 F Childhood 41 47 Mild Stiffness and  
slowness
Cores, rods, and  
dystrophy
c.1170G>C 
(p.(Lys390Asn))
NEM6-F12 M Adulthood 54 NA MildD Slowness Normal c.1107C>G 
(p.(Ile369Met))
NEM6-T01 M Childhood NA 52 Mild Stiffness NA c.1222C>T 
(p.(Arg408Cys))
NEM6-T02 F Childhood 32 33 Moderate Stiffness Cores and rods c.1222C>T 
(p.(Arg408Cys))
NEM6-T06 M Childhood NA 45 Mild Stiffness NA c.1222C>T 
(p.(Arg408Cys))
NEM6-T08 M Childhood NA 23 No muscle  
weakness
None NA c.1222C>T 
(p.(Arg408Cys))
NEM6-T09 M Unknown NA 49 Mild None NA c.1222C>T 
(p.(Arg408Cys))
NEM6-T10 M Childhood 30 36 Mild Slowness Cores and rods c.1222C>T 
(p.(Arg408Cys))
NEM6-T11 F Unknown NA 21 Mild Stiffness and  
slowness
NA c.1222C>T 
(p.(Arg408Cys))
CTRL-01 F NA 65 NA NA NA Normal NA
CTRL-02 M NA 50 NA NA NA Normal NA
CTRL-03 M NA 44 NA NA NA Normal NA
CTRL-04 M NA 50 NA NA NA Normal NA
CTRL-05 F NA 52 NA NA NA Normal NA
CTRL-06 F NA 51 NA NA NA Normal NA
All the biopsies that showed cores and/or rods also showed myopathic changes, including an increase of internal nuclei, fiber type disproportion, and fiber 
type I predominance. NA, not assessed. AMuscle weakness: proximal muscle groups are more affected than distal ones. Axial weakness is also present. No 
facial weakness. BMild: strength is at least MRC scale 4. CModerate: strength is MRC scale 3–4. DThis patient has predominantly distal weakness and thus 
differs from the other patients.
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lution-stimulated emission depletion (STED) microscopy (Supple-
mental Figure 2F). The calcium sensitivity of both slow-twitch and 
fast-twitch fibers was increased in NEM6 patients, as reflected 
by the higher pCa50 (Supplemental Figure 2, D and E). Note that 
we observed no changes in the passive stiffness of NEM6 muscle 
fibers (Supplemental Figure 3), suggesting that titin does not con-
tribute to the muscle stiffness experienced by NEM6 patients.
Importantly, the kinetics of relaxation after maximal activa-
tion were markedly slower in both slow-twitch and fast-twitch 
fibers of NEM6 patients when compared with control subjects. 
Figure 3G shows a typical relaxation trace of a patient’s and a 
control subject’s muscle fibers. The relaxation kinetics, reflected 
by the relaxation constant Krel, were approximately 3-fold slower 
in NEM6 fibers (Figure 3H). Thus, our findings on permeabilized 
NEM6 muscle fibers suggest that the mechanism contributing 
to slower muscle-relaxation kinetics in NEM6 patients is at least 
partly sarcomere-based and independent of muscle-fiber type.
Lower contractile force and slower relaxation kinetics in NEM6 myofibrils
Considering that a single fiber (diameter ~100 μm) is a collec-
tion of myofibrils (diameter ~1 μm; Figure 1A), contractile weak-
ness of single fibers could be caused by ultrastructural damage 
or misalignment of myofibrils. Furthermore, the determination 
of relaxation kinetics in fibers could be confounded by the dif-
ferent size of the NEM6 fibers compared with control fibers 
(Supplemental Figure 2, A–C), which affects diffusion time 
of solutions. Therefore, we also measured the contractility of 
Next, to study whether sarcomeric changes contribute to 
slower muscle-relaxation kinetics, we isolated permeabilized sin-
gle-muscle fibers from biopsies of NEM6 patients and activated 
these with exogenous Ca2+. Patient characteristics are shown in 
Table 1. Figure 3, A and B, shows EM images of muscle fibers from 
a control and an NEM6 patient, and Figure 3, C and D, show imag-
es of representative slow-twitch and fast-twitch NEM6 patient 
fibers that were used for mechanics. In NEM6 patients, the ratio 
of slow-twitch/fast-twitch fiber cross-sectional area was increased 
(Supplemental Figure 2A), indicating that the fibers used for 
mechanics reflect the fiber size distribution in the whole biopsy as 
determined by histology (Supplemental Figure 2, B and C). Next, 
fibers were exposed to incremental Ca2+ concentrations and the 
resulting forces were recorded. Maximal absolute force (i.e., force 
at pCa 4.5) was lower in fast-twitch fibers of NEM6 patients com-
pared with those of control subjects, but not in slow-twitch NEM6 
fibers compared with those of controls (Supplemental Figure 2, D 
and E). To correct for differences in fiber size, force was normal-
ized to the cross-sectional area of the fiber (i.e., tension). In NEM6 
patients, maximal tension of both slow-twitch and fast-twitch 
fibers was significantly lower than in fibers of control subjects 
(tension reduced by approximately 50%; Figure 3, E and F). The 
lower maximal active tension was not caused by shorter thin-fil-
ament lengths: the sarcomere-length dependence of maximal 
tension was not different between NEM6 and control fibers (Sup-
plemental Figure 2F). This finding was in line with the unaltered 
thin-filament length in NEM6 fibers, as determined by superreso-
Figure 2. TMS to study in vivo muscle-relax-
ation kinetics. (A) Schematic of the experimen-
tal setup for TMS to induce involuntary muscle 
relaxation (top). Typical, superimposed, force 
traces, and corresponding electromyogram 
(EMG) of a control subject (CTRL) and NEM6 
patient during maximal voluntary contraction 
and TMS-induced involuntary relaxation of the 
deep-finger flexors (middle and bottom). Note 
the motor-evoked potential on the EMG traces 
corresponding to the small superimposed twitch 
and the EMG silent period of approximately 
200 ms corresponding to the drop in force, after 
which voluntary force is generated again. Note 
the slower relaxation in the NEM6 patient. (B) 
Maximal force is lower in NEM6 patients than in 
controls, both in males and in females. (C) The 
peak relaxation rate (normalized to maximal 
force; pRR) is lower in NEM6 patients than in 
controls. (D) The time to 75% of maximal force 
(0.75 relaxation time) is longer in NEM6 patients 
than in controls. Orange circle corresponds to 
the NEM6 patient harboring the KBTBD13K390N 
mutation, white circles to those with the 
KBTBD13R408C mutation. Student’s t tests were 
performed between NEM6 and controls. *P < 
0.05. For detailed information on the number 
of samples and statistical tests and outcomes, 
please see Supplemental Table 1.
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patients was lower than that of control subjects. Thus, in addi-
tion to myofibrillar damage, myofibrillar dysfunction contrib-
utes to fiber weakness in NEM6 patients. Importantly, whereas 
the activating kinetics were on average similar between NEM6 
and control myofibrils (an example is shown in Figure 3M), the 
relaxation kinetics were slower in myofibrils of NEM6 patients 
than in those of control subjects (Figure 3, N and O; note that 
Figure 3N shows the same myofibril as in Figure 3M). Thus, our 
findings on individual myofibrils indicate that slower sarco-
meric relaxation kinetics contribute to slow muscle-relaxation 
kinetics in NEM6 patients.
NEM6 myofibrils. Figure 3, A B, I, and J, shows EM images of a 
control and an NEM6 muscle fiber (1 myofibril is highlighted). 
The EM image of the NEM6 muscle fiber reveals that areas with 
myofibrillar damage as well as areas with preserved myofibril-
lar ultrastructure are present within 1 muscle fiber (note that 
nemaline rods were frequently observed in EM images of the 
NEM6 patients; for a high-magnification example, see Supple-
mental Figure 4). We isolated single myofibrils from the intact 
areas of NEM6 muscle fibers and measured their contractile 
function (experimental arrangement shown in Figure 3K). As 
shown in Figure 3L, the maximal tension of myofibrils of NEM6 
Figure 3. Contractility assays to study relaxation kinetics of muscle fibers and myofibrils. (A) EM images from muscle fibers of a control and (B) a NEM6 
patient (note the areas with myofibrillar damage, indicated by asterisks). (C) Light microscopy images of a slow-twitch and (D) a fast-twitch NEM6 patient 
fiber that were used for contractility assays. (E) Maximal tension of both slow-twitch and (F) fast-twitch fibers from NEM6 patients was significantly lower 
than that of controls. (G) Typical relaxation trace of a NEM6 and a control muscle fiber. (H) The kinetics of relaxation after maximal activation — reflected 
by the relaxation constant Krel — were markedly slower in both slow-twitch and fast-twitch fibers of NEM6 patients when compared with controls. The 
orange, green, and yellow circles correspond to NEM6 patients harboring the KBTBD13K390N, KBTBD13E83Q, and KBTBD13I369M mutations, respectively. The 
white circles correspond to patients with the KBTBD13R408C mutation. (I) EM images indicate a myofibril (highlighted in white) from muscle fibers of control 
and (J) a NEM6 patient. Note that these EM images are higher magnifications of the same images in parts A and B, respectively. (K) Myofibril mounted 
between a force probe and length controller for contractility assays. (L) The maximal tension of myofibrils of NEM6 patients was lower than that of con-
trols. (M) Typical example of the activating kinetics and (N) the relaxation kinetics of a NEM6 and a control myofibril; note that activation and relaxation 
kinetics are from the same myofibril. (O) The relaxation kinetics were slower in myofibrils of NEM6 patients than in those of controls. Student’s t tests 
or Mann-Whitney U tests were performed between NEM6 and controls. *P < 0.05. For each biopsy, 4 to 12 muscle fibers/myofibrils were measured. For 
detailed information on the number of samples and statistical tests and outcomes, please see Supplemental Table 1.
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Structural changes in the thin filament suggest a stiffer thin 
filament in NEM6 patients.
As the findings from the fiber and myofibril studies point 
toward a sarcomere-based mechanism, we next determined 
whether structural changes in the thick and/or thin filament cause 
the slow-relaxation kinetics. At the Advanced Photon Source 
(Argonne National Laboratories), low-angle x-ray diffraction pat-
terns were obtained from preparations in which 28 fibers were 
mounted and aligned in 1 plane between 2 halves of EM grids. This 
approach allowed for high-quality equatorial and meridional dif-
fraction patterns (for example, see Figure 4A). The spacing of the 
equatorial reflections indicated that lattice spacing was not differ-
ent between NEM6 and control fibers (distance between thick fila-
ment planes (d1,0); see Figure 4B; 40.76 ± 0.37 vs. 40.95 ± 0.45 nm, 
respectively), and the equatorial intensity ratios indicated that the 
position of myosin heads between the thick and thin filaments was 
not different between NEM6 and control fibers (I1,1/I1,0, where I1,1 
indicates intensity resulting from 1,1 planes; see Figure 4B); 0.71 
± 0.13 vs. 0.68 ± 0.05, respectively). The meridional reflections 
indicated no spacing changes in thick-filament structure: both 
the myosin head displacement from the thick-filament backbone 
(M3 reflection: 14.53 ± 0.02 nm for control and 14.46 ± 0.03 nm 
for NEM6 fibers) and the thick-filament backbone periodicity (M6 
reflection, Figure 4C) were comparable in fibers of NEM6 patients 
and those of controls. Reflections from the thin filament, however, 
were different between NEM6 and control fibers: the actin layer 
line 6 (ALL6) indicating the left-handed pitch of the thin-filament 
helix was shorter in NEM6 than in control fibers (Figure 4D). 
Thus, low-angle x-ray diffraction studies suggest that the actin-
based thin filament is more tightly wound in NEM6 muscle fibers, 
a change that might reflect increased thin-filament stiffness.
Slower relaxation kinetics and stiffer thin filaments in muscle of 
Kbtbd13R408C mice
To further investigate the effect of the Dutch founder mutation 
KBTBD13R408C on muscle-relaxation kinetics and thin-filament 
stiffness, we engineered a Kbtbd13R408C-KI mouse model (Figure 
5A). Mice were studied at 9 months after birth (this age was cho-
sen, as in patients the phenotype is slowly progressive).
Basic characteristics of the model. Homozygous mice were born 
at significantly higher than Mendelian ratio (Supplemental Figure 
5A). Quantitative PCR showed that homozygous KI mice expressed 
only mutant Kbtbd13 and that heterozygous mice expressed 
approximately 50% of mutant and 50% of WT Kbtbd13 (Supple-
mental Figure 5C). KI mice had higher body weight than WT mice 
(Figure 5B). Soleus and diaphragm muscle weights were higher in 
KI compared with WT mice (Supplemental Figure 5D). Picrosiri-
us red–stained cryosections of m. soleus (representative images in 
Supplemental Figure 5E) showed a significantly increased area of 
extracellular matrix in KI compared with WT mice (14% ± 1% vs. 
12% ± 1%, respectively). Soleus muscle of KI mice had a lower per-
centage of slow-twitch (type 1) fibers than that of WT mice (28% 
± 2% vs. 60% ± 3%, respectively; Supplemental Figure 5E). The 
cross-sectional area of slow-twitch and fast-twitch (type 2A) fibers 
was larger in m. soleus of KI than of WT mice (Supplemental Figure 
5F). Similarly to what occurs in NEM6 patients (Supplemental Fig-
Figure 4. Determination of the nanostructure of muscle fibers. (A, top) Image of 28 NEM6 muscle fibers mounted and aligned in 1 plane between 2 halves 
of an EM grid (bottom); typical example of the resulting low-angle x-ray diffraction pattern. Note the well-resolved equatorial and meridional reflections. 
(B, left) Schematic of a sarcomere and the thin and thick filament, highlighting the structures that underlie the ALL6 reflection and the myosin (M6) 
reflection; (right) schematic representation of a cross section of muscle (thin filament in yellow, thick filament in pink), indicating the 1,0 and the 1,1 
reflections. (C) No change in M6 reflection (thick-filament backbone periodicity) is observed in fibers of NEM6 patients compared with those of controls. 
(D) The ALL6 reflection is reduced in NEM6 fibers compared with control fibers. The green circles and white circles correspond to NEM6 patients harboring 
the KBTBD13E83Q mutation and the KBTBD13R408C mutation, respectively. Student’s t tests or Mann-Whitney U tests were performed between NEM6 and 
controls. *P < 0.05. For detailed information on the number of samples and statistical tests and outcomes, please see Supplemental Table 1.
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ure 2C), in KI mice, the cross-sectional area of slow-twitch fibers 
was larger than that of fast-twitch fibers (Supplemental Figure 5G). 
Gömöri trichrome–stained sections of m. soleus showed nemaline 
bodies in muscle fibers (Figure 5C), a key characteristic of NEM. 
This finding was confirmed in fibers stained with phalloidin, show-
ing actin-positive nemaline bodies (Figure 5D). Thin-filament and 
thick-filament length in muscle of KI mice was comparable to that 
in WT mice, as determined by superresolution STED microscopy 
(Figure 5, E and F). Thus, the pathology observed in Kbtbd13-KI 
mice resembled NEM6 pathology.
Relaxation kinetics. Maximal tetanic tension (150 Hz) of m. 
soleus was comparable between KI and WT mice (Figure 5G), 
Figure 5. Characteristics of the Kbtbd13R408C KI mouse model. (A) Image of Kbtbd13R408C WT and homozygous KI mouse. (B) Body weight was significantly higher 
in KI mice. (C) Gomöri trichrome staining of m. soleus cryosections. Scale bars: 100 μm. KI section shows nemaline rods in many muscle fibers (examples indicat-
ed by white arrow). (D) Phalloidin staining of a permeabilized fiber of m. soleus; note the abundance of actin-positive nemaline rods. (E and F) STED microscopy 
images (deconvolved) of permeabilized fibers of m. soleus stained with phalloidin (Phal) (to stain the thin filament) and with a pan-specific myosin heavy chain 
(MHC) antibody (to stain the think filament); right panels show the resulting thin and thick-filament lengths as a function of sarcomere length. (G) Maximal 
tetanic tension (150 Hz) of m. soleus was comparable between WT and KI mice. (H) The maximal tetanic half-relaxation time was significantly longer in m. 
soleus of KI than in WT mice. (I) Typical example of a low-angle x-ray diffraction pattern obtained from m. soleus of a Kbtbd13-KI mouse; note the well-resolved 
reflection of the actin subunit spacing (2.7 nm). (J) The spacing of the ALL6 reflection is reduced in muscle of Kbtbd13R408C-KI mice. (K) The actin subunit spacing 
(2.7 nm) is reduced in muscle of Kbtbd13R408C-KI mice. (L) The change in the actin subunit spacing (Δ2.7 nm) during maximal tetanic activation is smaller in 
Kbtbd13R408C-KI mice, indicating less thin-filament extension. (M) Thin-filament stiffness is higher in muscle of Kbtbd13R408C-KI mice than in muscle of WT mice. 
Student’s t tests were performed between KI and WT mice. *P < 0.05. For detailed information on the number of samples and statistical tests and outcomes, 
see Supplemental Table 1.
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obtained per thin filament was significantly higher in KI muscle 
than in WT muscle (137.1 ± 2.8 pN vs. 124.6 ± 2.1 pN, respectively). 
Normalizing this force to the extension of the thin filament (Δ2.7 
nm reflection) showed that the force required to stretch the thin 
filament was significantly increased in KI muscle compared with 
WT muscle (Figure 5M). Thus, thin-filament stiffness is higher in 
muscle of KI mice.
Normal relaxation kinetics in muscle of Kbtbd13-KO mice
We also generated a Kbtbd13-KO mouse model to study the effect 
of absence of Kbtbd13 on muscle-relaxation kinetics. Similar-
ly to the mice of the Kbtbd13R408C KI model, mice were studied 9 
months after birth.
Basic characteristics of the model. Homozygous mice (KO; Sup-
plemental Figure 6A) were born at close to Mendelian ratio (Sup-
plemental Figure 6B). Gene Array Analyzer showed that Kbtbd13 
mRNA levels were severely reduced in KO mice (Supplemental 
Figure 6C). KO mice had lower body weight than WT mice (Sup-
plemental Figure 6D). Soleus muscle weights were lower in KO 
mice compared with WT mice (Supplemental Figure 6E), and 
quadriceps muscle weights were increased in KO mice.
Relaxation kinetics. The maximal tetanic tension (150 Hz) of 
m. soleus was reduced in KO mice (Supplemental Figure 6F), and 
the force-frequency relation was comparable between KO and WT 
mice (Supplemental Figure 6G). The level of SERCA1 was not sig-
nificantly different in KO compared with WT muscle (Supplemen-
tal Figure 6H). Importantly, the relaxation kinetics of both single 
twitches and maximal tetani were comparable between KO and 
WT mice (Supplemental Figure 6I). Thus, the relaxation kinetics of 
muscle of Kbtbd13-KO mice do not mimic those of Kbtbd13R408C-KI 
mice and NEM6 patients.
Relation between thin-filament stiffness and sarcomere relaxation 
kinetics
To evaluate whether changes in thin-filament stiffness affect sarco-
meric relaxation kinetics, simulations of paired compliant filaments 
were performed as described previously by Campbell (28) (for sche-
matic, see Supplemental Figure 7A). Increasing the stiffness of the 
actin filaments slowed the rate of relaxation from 2.53 s–1 to 4.37 s–1 
(Supplemental Figure 7B) without producing a substantial change 
in maximum isometric force (Supplemental Figure 7B). Thus, the 
combination of the results of the simulation experiments, the x-ray 
diffraction experiments, and the contractility assays in patient 
biopsies and in mouse models suggest that mutations in KBTBD13 
increase thin-filament stiffness and that increased thin-filament 
stiffness can slow sarcomeric relaxation kinetics.
KBTBD13 binds to actin
In order to examine the potential for KBTBD13 to bind to actin, 
we turned to homology modeling, anticipating that structur-
al features of the protein provide insight into potential interac-
tions. Given the low sequence similarity between KBTBD13 and 
other proteins (<30%), 3 independent programs with different 
template starting structures were used for the modeling process. 
We note a high degree of structural similarity between the struc-
tured regions of our 3 resulting models (root mean square devia-
tion [R.M.S.D.] < 0.8 Å) that supports the relevance of our model. 
and the force-frequency curve was shifted to the left (Supplemen-
tal Figure 5H). Importantly, similarly to observations in NEM6 
patients, the relaxation kinetics of m. soleus after maximal tetanic 
stimulation were slower in KI mice than in WT mice (Figure 5H). 
After single-twitch stimulation, relaxation kinetics were also slow-
er in KI mice compared with WT mice (Supplemental Figure 5I). 
The level of SERCA1 was not significantly different in KI com-
pared with WT muscle (Supplemental Figure 5J).
Thin-filament stiffness. Next, we determined the structure of 
the thin and thick filaments in muscle of KI and WT mice. Low-an-
gle x-ray diffraction patterns were obtained from intact m. soleus in 
the relaxed state and at maximal tetanic activation (Figure 5I). The 
meridional reflections indicated that, in the relaxed state, the struc-
ture of the thick filament was different in KI than in WT muscle: the 
thick-filament backbone periodicities (M6 reflection and the 2.8 
nm reflection; Supplemental Figure 5, K and L) were both shorter 
in KI muscle than in WT muscle. However, the relative extension 
of the thick filament during maximal tetanic activation was compa-
rable between KI and WT muscle (Δ2.8 nm; Supplemental Figure 
5M), suggesting a comparable thick-filament stiffness.
Reflections from the thin filament were also different between 
KI and WT muscle. Similarly to the observations in NEM6 muscle, 
the ALL6 reflection was shorter in KI than in WT muscle (Figure 
5J). Importantly, working with intact mouse muscles allowed us to 
determine actin subunit spacings (i.e., 2.7 nm reflections, Figure 
5K). This reflection could not be resolved in the x-ray diffraction 
patterns of permeabilized human muscle fibers (Figure 4A). We 
took advantage of this opportunity and observed that in relaxed 
muscle, the actin subunit spacing was shorter in KI than in WT 
mice (Figure 5K), supporting our notion that the shortened ALL6 
reflection indicates a more compact thin filament. Then, to study 
whether the thin filament is stiffer in KI mice, we analyzed the 
change in the 2.7 nm reflection during maximal tetanic activation. 
As shown in Figure 5L, the change in this reflection (Δ2.7 nm) was 
reduced in KI muscle. Thus, this indicates that during activation, 
the thin filament extends less in KI muscle than in WT muscle. 
Next, we used the Δ2.7 nm data to calculate the longitudinal stiff-
ness of the thin filaments. To this end, it is important to investigate 
how the isometric tension is distributed over the myofilaments in 
the sarcomere. Hence, an ultrastructural analysis was performed 
on electron micrographs of KI and WT m. soleus cross sections. No 
significant difference was observed in myofibrillar fractional area 
in KI compared with WT muscle (intermyofibrillar mitochondria: 
3.6% ± 0.1% vs. 2.4% ± 0.4%, respectively; subsarcolemmal mito-
chondria: 8.9% ± 0.5% vs. 7.9% ± 0.6%, respectively). We then cal-
culated the force per individual thin filament in activated muscle. 
Briefly, the unit cell area of the myofilament lattice was calculat-
ed from the d1,0 equatorial spacing (in relaxed state: 34.2 ± 0.1 vs. 
32.7 ± 0.2 nm, KI vs. WT, respectively) according to Millman (26), 
with the number of unit cells per muscle cross section equaling the 
myofibril area (which was calculated using the mitochondrial area 
and the extracellular matrix area) divided by the unit cell area. 
Furthermore, the tension distribution along the thin and thick fil-
aments was determined from their lengths (which were compara-
ble between KI and WT muscle; Figure 5, E and F) and the overlap 
between them. For myofilament overlap, we assumed a sarcomere 
length of 2.8 μm (based on Kiss and coworkers; ref. 27). The force 
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found in limulus sperm (29). To assess the similarities between 
the scruin and KBTBD13 β propeller motifs, we also developed a 
homology model for the scruin protein. A different template struc-
ture was used for constructing the scruin homology model to avoid 
bias. We found several similarities between the β propeller motif 
of KBTBD13 and scruin (Figure 6A). In both β propeller motifs, 
Similar to other proteins that contain repeating Kelch motifs, the 
resulting KBTBD13 homology model contains a β propeller struc-
ture. The β propeller is located in the C terminal portion, while the 
BTB motif adopts a more loosely defined zinc finger in the -termi-
nal region. Intriguingly, protein sequence analysis revealed sim-
ilarities between KBTBD13 and the actin-binding protein scruin, 
Figure 6. Effect of KBTBD13 on sarcomere structure and function. (A) Homology modeling reveals that KBTBD13 β propeller motifs (left) have striking 
similarities with those of the actin-binding protein scruin in limulus sperm (middle). KBTBD13 has cysteine residue (Cys367) located in nearly the exact same 
position as scruin (Cys837, right). (B) SDS-PAGE image after pulldown assay in a mouse muscle lysate (muscle lys.). One unique band (*) was identified, excised, 
and analyzed with mass spectrometry. Actin was prominently present in excised band. (C, left). Amounts of KBTBD13 (gray) and KBTBD13R408C (blue) bound to 
actin versus free KBTBD13 were plotted and fitted. The shared fit is shown in black. (C, right) Western blot of KBTBD13 in pellet and supernatant fraction (in 
presence of actin, P+, and S+, respectively) and pellet fraction in absence of actin (P–) (lanes 1-3). Lanes 6–8 show dose-dependent detection of serial dilution 
of recombinant KBTBD13. (D) APEX-based EM of zebrafish expressing GFP-tagged KBTBD13. Positive cells stained dark in electron micrographs. Note that in 
cells, myofibrils in particular show dark staining. Scale bar: 1 μm. Top right: To increase contrast between KBTBD13-positive and -negative areas, images were 
converted from gray scale to spectrum scale, with KBTBD13 in light blue. Below, right: high magnification of myofibrillar compartment. Scale bar: 0.3 μm. Within 
myofibrils, A-band and I-band show labeling, indicating that KBTBD13 binds to thin filament and thick filament. Furthermore, z-discs, where thin filaments 
from adjacent sarcomeres overlap, show strong labeling. Below, left: high magnification of myofibrillar compartment of negative cell. Scale bar: 0.3 μm. (E) 
Left: representative image of actin filaments in solution. Inset illustrates determination of parameters required to calculate persistence length (Lp) of actin 
filaments. Right: KBTBD13WT protein does not affect Lp, but KBTDB13R408C increases Lp of actin filaments. (F). Left: relaxation traces of 2 segments of same 
permeabilized muscle fiber: one incubated with recombinant KBTBD13WT, the other with recombinant KBTBD13R408C. Right: In healthy control muscle, incubation 
with KBTBD13R408C slows relaxation kinetics. In NEM6 muscle, incubation with KBTBD13WT does not affect relaxation kinetics. Student’s t tests or Mann-Whitney 
U tests were performed. For detailed information on number of samples and statistical tests and outcomes, see Supplemental Table 1.
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KBTBD13 binds to the thin filament and the thick filament. Fur-
thermore, the z-discs, where thin filaments from adjacent sarco-
meres overlap, show strong labeling. Note that to increase the con-
trast between KBTBD13-positive and -negative areas, the “normal” 
EM image (Figure 6D) was converted from gray scale to spectrum 
scale (Figure 6D), with KBTBD13 in light blue. The EM images of 
transgenic Kbtbd13408C-EGFP fish showed localization comparable 
to that of the transgenic Kbtbd13WT-EGFP fish (Supplemental Fig-
ure 8C). Thus, the data from these experiments support the confo-
cal, pull-down, and cosedimentation data showing that KBTBD13 
binds to actin in the thin filaments of muscle.
KBTBD13R408C increases the flexural rigidity of actin filaments
To study whether binding of KBTBD13 directly affects the struc-
ture of thin filaments, we tested the effect of KBTBD13WT and 
KBTBD13R408C on the flexural rigidity (assessed by determining 
the persistence length) of actin filaments in solution. Figure 6E 
shows a typical image of actin filaments in solution (Supplemen-
tal Videos 4–6 show actin filaments in solution). The results show 
that KBTBD13WT does not change the persistence length of actin 
filaments compared with that of actin filaments not exposed to 
KBTBD13WT (Figure 6E). However, KBTBD13R408C significant-
ly increased the persistence length of actin filaments (Figure 
6E). These findings show that binding of KBTBD13R408C directly 
increases the stiffness of actin filaments.
KBTBD13R408C slows relaxation of human muscle fibers
To study whether slower relaxation kinetics in NEM6 muscle 
fibers are a direct effect of mutant KBTBD13, we incubated per-
meabilized quadriceps single-muscle fibers from control subjects 
and NEM6 patients with either KBTBD13WT or KBTBD13R408C and 
studied contractile function (Figure 6F). In fibers from NEM6 
patients, the maximal forces were comparable between groups 
(108 ± 20 mN/mm2 for fibers incubated with KBTBD13WT and 120 
± 17 mN/mm2 for fibers incubated with KBTBD13R408C). Incubation 
with KBTBD13WT slightly increased the relaxation kinetics com-
pared with incubation with KBTBD13R408C (Figure 6F); however, 
this difference did not reach significance. In fibers from control 
subjects, maximal forces were also comparable between groups 
(125 ± 9 mN/mm2 for fibers incubated with KBTBD13WT and 114 
± 9 mN/mm2 for fibers incubated with KBTBD13R408C). Howev-
er, incubation with KBTBD13R408C significantly slowed relaxation 
kinetics compared with incubation with KBTBD13WT (Figure 6F).
Together, these findings suggest that in the NEM6 fibers, 
the KBTBD13R408C protein was not replaced by KBTBD13WT pro-
tein, but the KBTBD13WT protein was added to the endogenous 
KBTBD13R408C protein. Apparently, the amount of endogenous 
KBTBD13R408C protein in the NEM6 fibers was sufficient to main-
tain the slow-relaxation kinetics. Similarly, in the healthy fibers, 
KBTBD13WT protein was likely not replaced by KBTBD13R408C pro-
tein, but the KBTBD13R408C protein was added to the endogenous 
KBTBD13WT protein. This addition was sufficient to exert an effect 
on sarcomere relaxation kinetics. These findings are in line with 
the R408C mutation being a dominant mutation.
Finally, it is important to note that in the experiments with per-
meabilized muscle fibers, the cytosol is replaced by experimental 
solutions. Therefore, our findings suggest that KBTBD13R408C is 
the majority of cysteines were contained internally within the β 
sheets. In scruin, a single cysteine (Cys837) located in a loop at the 
surface of the β propeller was found to be important for the inter-
action with filamentous actin (30). Importantly, KBTBD13 has a 
single cysteine (Cys367) located in a similar position relative to 
scruin Cys837 (Figure 6A). Scruin is known to bind to filamentous 
actin, and Cys837 is important for this binding. These findings 
suggest that KBTBD13 might interact with actin. Strikingly, the 
location of 3 KBTBD13 mutations (I369M, K390N and R408C) 
are in close proximity to Cys367 (Figure 6A).
To test whether KBTDB13 binds to actin, we performed pull-
down assays with full-length KBTBD13 and muscle lysates. The 
pulled down proteins were separated on an SDS-PAGE gel (Fig-
ure 6B). One unique band was observed at a height that corre-
sponds to a molecular weight of 40–45 kD. The proteins in this 
band were identified by mass spectrometry. Actin was one of the 
major proteins identified. Then, to validate whether KBTBD13 
also binds to filamentous actin in vitro and whether the most prev-
alent disease-causing mutation affects this binding, we expressed 
full-length KBTBD13 and KBTBD13R408C and performed a cosed-
imentation assay with filamentous actin. The data demonstrate 
that both KBTBD13 and KBTBD13R408C bind to filamentous actin 
with comparable affinities (Figure 6C). As actin-binding proper-
ties were not different between KBTBD13 and KBTBD13R408C, we 
fitted a single curve using the data from both proteins (shared 
fit). The resulting binding curve showed a Kd of 3.25 ± 19.08 μM 
to actin and a maximum binding of approximately 1.08 ± 1.92 μM 
KBTBD13 to 8 μM actin, suggesting a stoichiometry of approxi-
mately 1 KBTBD13 molecule to 8 actin molecules. Recombinant 
KBTBD13 also showed some sedimentation in the absence of 
actin (Figure 6C, P–); however, in the presence of actin (P+), great-
er amounts of KBTBD13 were consistently detected in the pellet 
and all data points are corrected for the amount of KBTBD13 sed-
imenting in the absence of actin at each concentration. Glutathi-
one S-transferase (GST) alone did not sediment in the presence or 
absence of actin. Thus, our findings suggest that KBTBD13 is an 
actin-binding protein.
We next determined the localization of KBTBD13 in muscle 
fibers. We were unable to detect KBTBD13 using antibodies (we 
tested commercially available antibodies and 2 custom-made 
antibodies). Therefore, we generated transgenic Kbtbd13- EGFP 
and Kbtbd13R408C-EGFP zebrafish. Note that in these fish, the 
fibers display mosaic expression of KBTBD13; hence, only few 
cells show labeling. Confocal microscopy analysis suggests that 
both KBTBD13 and KBTBD13R408C localize to the myofibrils, and 
the fluorescence pattern, throughout the sarcomere with a peak at 
the Z-disc, appears consistent, with colocalization with actin (Sup-
plemental Figure 8, A and B). Then, to more accurately localize 
KBTDB13, we made use of APEX — a peroxidase enzyme that can 
be used to stain samples for EM. The peroxidase was coupled to a 
GFP-binding peptide that then allowed for EM localization of GFP-
tagged Kbtbd13. We made a transgenic line of fish that contains the 
GFP-binding APEX protein and injected these with Kbtbd13-EGFP. 
As shown in Figure 6D, the EM-APEX data indicate that KBTBD13 
localizes to the myofibrils. Within the myofibrils, the A-band 
(mainly myosin-based thick filaments) and the I-band (mainly 
actin-based thin filaments) showed dark labeling, indicating that 
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NEM6 patients. In addition, the findings from histology assays 
suggest that the relative increase in the area of slow-twitch muscle 
fibers might contribute as well (slow-twitch fibers have slower con-
tractile kinetics than fast-twitch fibers). However, slow-twitch fiber 
predominance is a common feature in all forms of NEM and in con-
genital myopathies in general, whereas clinically, impaired muscle 
relaxation is specific for NEM6, indicating that the increased area 
of slow-twitch muscle fibers is unlikely to account for the NEM6 
phenotype. The findings from contractility assays in fibers and 
myofibrils isolated from patient biopsies, assays in which con-
founding effects of Ca2+ handling by the sarcoplasmic reticulum 
are absent, revealed that changes in the kinetics of thick-thin-fil-
ament detachment are an important contributor to the impaired 
relaxation kinetics in NEM6 muscle. These changes were present 
in both slow- and fast-twitch fibers. Thus, impaired sarcomeric 
relaxation kinetics are a major contributor to slowed muscle-relax-
ation kinetics in NEM6, irrespective of muscle fiber type.
Thin-filament structure is altered in NEM6 muscle. Low-angle 
x-ray diffraction studies on muscle fibers revealed that the cause 
of slower thick-thin filament detachment kinetics might involve 
structural changes of thin filaments in NEM6 muscle. The posi-
tion of ALL6, reflecting the left-handed pitch of the thin-filament 
helix (Figure 4D), was reduced in NEM6 muscle fibers from 
approximately 5.88 to approximately 5.85 nm, indicating that 
thin filaments are more tightly wound. This compression (~0.5%, 
which translates to ~6 nm on a thin-filament length of 1300 nm 
and is therefore not detectable with STED microscopy, Supple-
mental Figure 2F) might affect the stiffness of thin filaments. The 
low-angle x-ray diffraction experiments in the newly generated 
Kbtbd13R408C-KI mouse model provided conclusive evidence that 
thin-filament stiffness is increased in muscle with KBTBD13R408C. 
First, Kbtbd13R408C-KI mice closely phenocopy NEM6 pathology, 
including nemaline bodies in muscle fibers and slow kinetics of 
muscle relaxation (Figure 5). Second, the simultaneous assess-
ment of force generation and actin subunit spacing (the 2.7 nm 
reflection) during low-angle x-ray diffraction experiments in the KI 
mice revealed that the stiffness of the thin filament was increased 
from 37 pN*nm–1*μm–1 in WT muscles to 49 pN × nm–1 × μm–1 in 
KI muscles (Figure 5M). The value for WT muscle is comparable 
to that recently reported for murine m. soleus (30 pN × nm–1 × 
μm–1; ref. 27). On the other hand, the value for KI muscle is likely 
an underestimation, as in the determination of myofibrillar area 
(required to calculate the number of individual thin filaments), 
we did not take into account the area occupied by nemaline rods. 
Figure 5, C and D, suggests that this area is significant. Thus, the 
actual stiffness of thin filaments in KI muscle might even be con-
siderably higher than the value here reported.
To evaluate whether the increased thin-filament stiffness 
slows muscle-relaxation kinetics, we turned to simulations of sar-
comere contractility kinetics, using the model of paired compliant 
thin and thick filaments described by Campbell (28) (Supplemen-
tal Figure 7). In these simulations, the rate of relaxation reflects 
the speed at which the thick-filament–based myosin heads detach 
from actin-binding sites on the thin filament. This detachment 
rate is accelerated by allowing myosin heads to move relative to 
actin. In real muscles, the relative movement between the myo-
sin heads and actin-binding sites results from, among others, 
unlikely to act through ubiquitination or disruption of filament 
assembly/turnover, but rather that it regulates relaxation kinetics 
by direct binding to sarcomeric structures.
Discussion
With the use of TMS, we established that the origin of impaired 
muscle-relaxation kinetics in NEM6 myopathy is myogenic. The 
pathomechanism underlying the observed impaired muscle-re-
laxation kinetics was studied using contractility assays in perme-
abilized muscle fibers and myofibrils isolated from patient biop-
sies. We discovered that impaired muscle relaxation is sarcomere 
based. By applying a combination of low-angle x-ray diffraction, 
superresolution microscopy, modeling of muscle kinetics, and 
proteomics with genetically modified mouse models and zebra-
fish, we showed that KBTBD13, the protein affected in NEM6, is 
an actin-binding protein. Mutations in KBTBD13 slowed relax-
ation kinetics of muscle through direct, structural effects on the 
actin-based thin filament. We propose that this pathomechanism 
is central to NEM6 pathology.
Impaired muscle relaxation in NEM6 is sarcomere based. In vivo 
muscle-relaxation properties were considerably slower in NEM6 
patients compared with healthy controls. TMS has been used 
before to measure physiological muscle-relaxation kinetics (25, 
31–35), but this is the first time, to our knowledge, that this tech-
nique has been used to assess muscle relaxation in myopathy. TMS 
eliminates all influences of the nervous system on muscle relax-
ation. Consequently, our findings demonstrate that the impaired 
relaxation kinetics in NEM6 patients are myogenic in nature. With 
a doubling of relaxation time, the muscle slowness was severe, 
with profound effects on mobility, as shown in the Supplemental 
Videos. The NEM6 phenotype, i.e., impaired muscle-relaxation 
kinetics and the absence of severe weakness (Table 1), distinguish-
es NEM6 from other nemaline myopathies.
The kinetics of muscle relaxation depend on the kinetics of 
Ca2+ reuptake by the sarcoplasmic reticulum and the kinetics of 
thick-filament detachment from the thin filament. Activity levels 
of phospholamban, a natural inhibitor of the Ca2+ pumps in the 
sarcoplasmic reticulum, were increased in NEM6 muscle biopsies 
(Supplemental Figure 1F), suggesting that slowed Ca2+ reuptake 
might contribute to the slow-relaxation kinetics in muscle of 
Figure 7. Graphic summary of the proposed pathomechanism in NEM6. 
This study identified KBTBD13 as an actin-binding protein. Mutations in 
KBTBD13 alter the structure of the thin filament, thereby impairing muscle 
relaxation kinetics.
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ing suggested that KBTBD13 binds to actin (Figure 6A), which 
was confirmed by pull-down assays and cosedimentation assay 
with filamentous actin (Figure 6, B and C). APEX-based EM 
of GFP-tagged mutant and WT KBTBD13 in zebrafish showed 
localization consistent with KBTBD13 binding to actin in intact 
muscle fibers (Figure 6D). Of interest, the binding assay predict-
ed a 1:8 stoichiometry of KBTBD13 to actin. This is similar to the 
stoichiometry of the regulatory proteins tropomyosin and tropo-
nin to actin (both 1:7). Tropomyosin, troponin, and 7 actin mono-
mers together form one regulatory unit, and a serial sequence of 
these regulatory units control thin-filament activation and deac-
tivation. This raises the intriguing possibility of KBTBD13 acting 
in concert with actin, tropomyosin, and troponin to fine-tune 
the kinetics of muscle contractility. It should be noted that the 
APEX-based EM studies in zebrafish suggested that KBTBD13 
also localizes to the cytoplasm and the thick filament (Figure 
6D). Indeed, the low-angle x-ray diffraction studies in Kbtbd13-
KI mice showed reduced thick-filament backbone periodicities 
(M6 and 2.8 nm reflections; Supplemental Figure 5, K and L), 
suggesting an altered structure. Thick-filament stiffness, how-
ever, was unaffected, as indicated by the unaltered Δ2.8 nm 
reflection during muscle activation (Supplemental Figure 5M). 
The functional significance of KBTBD13 localization to the thick 
filament is unclear and warrants further investigation. The cyto-
plasm localization is in agreement with previous work from Sam-
buughin et al. in so-called “premyofibrils” of c2c12 cells, which 
suggested cytosolic localization, but no myofibrillar localization 
(20). Perhaps localization of KBTBD13 depends on the devel-
opmental stage of muscle and KBTBD13 doesn’t localize to the 
actin filament until after the premyofibril stage.
To date, 3 disease-causing mutations in KBTBD13 have been 
described, of which the p.R408C mutation is the most frequently 
described one. Here, we report 2 mutations in KBTBD13: p.I369M 
and p.E83Q. Notably, I369 is located near K390, R408, and the 
cysteine that might be responsible for actin binding (C367, Figure 
6A). This observation, in combination with the observed structural 
and functional changes in the actin-based thin filament in muscle 
fibers from NEM6 patients and Kbtbd13R408C-KI mice, supports 
our hypothesis that KBTBD13 mutations affect relaxation kinetics 
through direct effects on the thin filament. The majority of patients 
included in the present study have the KBTBD13R408C mutation 
(Table 1). For this reason, we generated recombinant KBTB-
D13R408C and observed that its binding affinity for filamentous 
actin was comparable to that of KBTBD13WT, despite the mutation 
being close to C367 (Figure 6A). This suggests that the mechanism 
underlying the observed slowing of relaxation kinetics of human 
muscle fibers exposed to KBTBD13R408C (Figure 6F) does not 
involve reduced or increased binding to actin of mutant KBTBD13, 
but rather an effect on the structure of the thin filament once 
bound to actin. The nature of this effect is unknown. We propose 
that KBTBD13R408C is a gain-of-function mutation. This proposition 
is based on the observation that (a) the Kbtbd13R408C-KI mice do not 
phenocopy the mice that are deficient in KBTBD13 (e.g., unlike the 
Kbtbd13-KO mice, the Kbtbd13R408C mice have slower kinetics of 
muscle relaxation; Figure 5H); and (b) KBTBD13WT protein did not 
affect the flexural rigidity of thin filaments, whereas KBTBD13R408C 
increased the rigidity (Figure 6E). Thus, KBTBD13WT protein does 
thick- and thin-filament compliance (inverse of stiffness). In brief, 
during sarcomeric relaxation, the Ca2+ concentration near the sar-
comeres falls. If a myosin head detaches under these conditions, 
the binding site on actin has a high probability of deactivating 
before another myosin head can bind. Thus, myosin heads that 
are detached by movement of thick filaments relative to thin fil-
aments (due to thin and thick-filament compliance, i.e., the recip-
rocal of stiffness) are not replaced. The prevailing force must thus 
be borne by a smaller number of myosin head–actin interactions. 
This in turn stretches the remaining interactions and accelerates 
their detachment. The net result is a positive feedback loop that 
causes thin-thick-filament detachment. Our simulation results 
suggest that increasing thin-filament stiffness decreases the pos-
itive feedback and slows the rate of relaxation. To our knowledge, 
this is the first study that links increased thin-filament stiffness 
with slow sarcomeric relaxation kinetics. The findings obtained 
provide insights into the mechanisms underlying the previously 
reported fast relaxation kinetics of myofibrils from nebulin-defi-
cient mice (36): in the absence of nebulin, the thin filaments were 
more compliant (27).
It should be noted that the magnitude of thin-filament stiffen-
ing in NEM6 muscle is unknown, and therefore we modeled the 
effect of very stiff thin filaments. Hence, we cannot rule out that in 
NEM6 muscle, the effect of thin-filament stiffness on relaxation 
kinetics is less pronounced than the model predicts. Furthermore, 
in addition to thin-filament stiffness, increased thin-filament 
activation in NEM6 muscle might contribute to the slow-relax-
ation kinetics. Interestingly, increased thin-filament activation 
would not only slow-relaxation kinetics, but would also increase 
the calcium sensitivity of force, as indeed observed in NEM6 
fibers (Supplemental Figure 2, D and E) and indirectly in muscle 
of Kbtbd13R408C-KI mice (Supplemental Figure 5H). We speculate 
that the KBTBD13R408C-induced increased flexural rigidity of thin 
filaments might play a role (Figure 6E; 30% increase in the per-
sistence length of actin filaments exposed to recombinant KBTB-
D13R408C protein). This speculation is based on previous reports 
indicating that, similarly to KBTBD13R408C, the actin-binding 
protein phalloidin (a) increases the persistence length of actin fil-
aments (37) with (b) a concomitant increase of thin-filament acti-
vation (38). Finally, the KBTBD13-based effects on thin-filament 
activation and on thin-filament stiffness might act in concert to 
modulate muscle-relaxation kinetics in NEM6 muscle, a possibili-
ty that warrants further investigation.
KBTBD13 modulates thin-filament function
Our data indicate that the increased stiffness of thin filaments 
in NEM6 muscle is a direct consequence of binding of mutant 
KBTBD13 to actin. KBTBD13 is a muscle-specific protein com-
posed of an N-terminal BTB domain and a C-terminal Kelch- 
repeat domain. The role of KBTBD13 in muscle structure and 
function has been largely unknown. Previous work suggested 
that KBTBD13 is a substrate adaptor for Cullin-3, a muscle-spe-
cific ubiquitin ligase, and thereby implicated the ubiquitin/pro-
teasome pathway in the pathogenesis of KBTBD13-associated 
NEM (24, 39). The present study reveals that KBTBD13 has addi-
tional functions, namely that of an actin-binding protein that 
modulates the relaxation kinetics of muscle. Homology model-
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murine experiments were approved and conducted under the supervi-
sion of the University of Arizona IACUC and followed the NIH guide-
lines Using Animals in Intramural Research.
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not affect thin-filament structure and muscle-relaxation kinetics, 
whereas KBTBD13R408C slows muscle-relaxation kinetics by direct 
effects on thin-filament structure.
How the putative role of KBTBD13 in ubiquitin-ligase activ-
ity is involved in these effects on muscle-relaxation kinetics is 
unknown. An important aspect of the experimental approach 
was that in the assays in which the effect of KBTBD13 on relax-
ation was studied, permeabilized muscle fibers were used (Fig-
ure 6F). In permeabilized muscle fibers, the cytosol is replaced 
by an experimental solution in which no ubiquitin and conjuga-
tion enzymes are present. Thus, in this context, the modulation 
of relaxation kinetics by KBTBD13R408C protein (Figure 6F) must 
be a consequence of direct binding to sarcomeric proteins, pre-
sumably actin, rather than of ubiquitin ligase or other cytosolic 
activity. Note that the newly identified mutation E83Q is located 
in the BTB domain of KBTBD13, whereas the other 4 mutations 
are located in the Kelch domain. The BTB domain interacts with 
Cul3, whereas the Kelch domain provides an adaptor function for 
substrate recognition (24, 39). Based on our findings, we postulate 
that actin is targeted by KBTBD13’s Kelch domain, and we spec-
ulate that the mutation in the BTB domain may affect sarcomere 
function through changes in ubiquitination.
In conclusion, this study identified KBTBD13 as an actin-bind-
ing protein, a property that when affected by mutations alters the 
structure of the thin filament, thereby impairing muscle-relax-
ation kinetics (Figure 7). We propose that this pathomechanism is 
central to the NEM6 phenotype.
Methods
Please see the Supplemental Methods for a detailed description 
of TMS, muscle biopsies, permeabilized muscle-fiber mechanics, 
myosin heavy chain isoform composition determination, myofibril 
mechanics, recombinant KBTBD13 and KBTBD13R408C protein expres-
sion, actin and KBTBD13/KBTBD13R408C cosedimentation assay, pull-
down assay with recombinant KBTBD13 proteins, mass spectrome-
try, KBTBD13 and KBTBD13R408C incubation assay in human muscle 
fibers, generation of the Kbtbd13-KO and Kbtbd13R408C-KI mouse mod-
els, intact muscle mechanics, homology modeling, KBTBD13 localiza-
tion in zebrafish, antibodies used for Western blot, flexural rigidity of 
actin filaments, EM, immunohistochemistry, Ca2+ reuptake, low-angle 
x-ray diffraction, and stimulated emission-depletion microscopy.
Statistics. Data are presented as mean ± SEM or as median with 
interquartile range (normally distributed, not normally distributed, 
respectively). For statistical analyses, 2-tailed t tests or Mann-Whitney 
U tests were used. A P value of less than 0.05 was considered statisti-
cally significant. For detailed information on the number of samples 
and statistical tests and outcomes, please see Supplemental Table 1.
Study approval. Experimental procedures for human studies 
were approved by the institutional ethics committee and performed 
in accordance with ethical standards laid down in the Declaration 
of Helsinki. All biopsies were collected following informed consent 
supervised by the Radboud University Institutional Review Board. All 
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